NEUARTIGE TLR9-AGONISTEN

Patent europeic · EP4087931 · En vigur

Inscripziun en il register

Numer da publicaziun
EP4087931
Numer da la dumonda
EP21738230
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
08-01-2021
Publitgà
16-11-2022
Concedì
25-12-2024
La protecziun finescha il pli tard
07-01-2041
Proxima taxa annuala scadenta
31-01-2027
Classas IPC
C12N 15/117 (2010.01)
A61K 31/711 (2006.01)
A61P 37/00 (2006.01)
Prioritad
JP 2020002715 10.01.2020
Dumonda PCT
PCT/JP2021/000543 08.01.2021
Publicaziun PCT
WO2021/141121 15.07.2021
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 01-02-2026

    Midada

    Published in Swissreg on 01.02.2026

  2. 05-11-2025

    Midada

    Published in Swissreg on 05.11.2025

  3. 01-02-2025

    Midada

    Published in Swissreg on 01.02.2025

  4. 13-01-2025

    Represchentant inscrit

    Representative
    Dennemeyer AG, Bahnhofstrasse 23, 6300 Zug

    Published in Swissreg on 13.01.2025

  5. 25-12-2024

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 25.12.2024

Partidas

Possessur

SBI Biotech Co., Ltd.

1-6-1, Roppongi, Minato-ku, Tokyo, 106-6015, JP

Represchentant

Dennemeyer AG

Bahnhofstrasse 23, 6300 Zug

Inventur

ESASHI Eiji

Tokyo 106-6015, JP

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.